Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
489
Views
7
CrossRef citations to date
0
Altmetric
Letters to the Editor

Epstein–Barr virus infection is associated to patients with multiple myeloma and monoclonal gammopathy of undetermined significance

Giuseppe Mamelia Department of Biomedical Sciences, University of Sassari, Sassari, Italy
,
Claudio Fozzab Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Magdalena Niegowskaa Department of Biomedical Sciences, University of Sassari, Sassari, Italy
,
Giovanna Cordab Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Maria Francesca Rudab Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Francesca Barraqueddub Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Laura Dessìb Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Luigi Poddab Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
,
Fausto Doreb Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
&
Leonardo A. Sechia Department of Biomedical Sciences, University of Sassari, Sassari, ItalyCorrespondence[email protected]
 show all
Pages 466-469 | Received 07 Mar 2016, Accepted 12 May 2016, Published online: 07 Jun 2016

References

  • Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–119.
  • Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–1127.
  • Vockerodt M, Yap LF, Shannon-Lowe C, et al. The Epstein–Barr virus and the pathogenesis of lymphoma. J Pathol. 2015;235:312–322.
  • Sekiguchi Y, Shimada A, Ichikawa K, et al. Epstein–Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature. Int J Clin Exp Pathol. 2015;8:2090–2102.
  • García-Álvarez KG, Garibaldi-Covarrubias R, Flores-Márquez MR, et al. Plasma cell myeloma associated with Epstein–Barr virus infection in an 11-year-old girl. Pediatr Dev Pathol. 2012;15:339–342.
  • Sasaki S, Hashimoto K, Nakatsuka S, et al. Plasmablastic extramedullary plasmacytoma associated with Epstein–Barr virus arising in an immunocompetent patient with multiple myeloma. Intern Med. 2011;50:2615–2620.
  • Ancín I, Sarrá J, Peris J, et al. Demonstration of Epstein–Barr virus in a case of multiple myeloma after renal transplantation. Haematologica. 2000;85:773–774.
  • Ventura G, Lucia MB, Damiano F, et al. Multiple myeloma associated with Epstein–Barr virus in an AIDS patient: a case report. Eur J Haematol. 1995;55:332–334.
  • Melato M, Paladini G. Multiple myeloma following reactivated Epstein–Barr virus infection in a renal-transplant recipient. Haematologica. 1986;71:241–243.
  • Sadeghian MH, Ayatollahi H, Keramati MR, et al. The association of Epstein–Barr virus infection with multiple myeloma. Indian J Pathol Microbiol. 2011;54:7204.
  • Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72:1012–1019.
  • Lin JH, Lin JY, Chou YC, et al. Epstein–Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1. Blood. 2015;125: 2228–2238.
  • Geng L, Wang X. Epstein–Barr virus-associated lymphoproliferative disorders: experimental and clinical developments. Int J Clin Exp Med. 2015;8:14656–14671.
  • Fukuda M, Longnecker R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol. 2004;78:1697–1705.
  • Portis T, Longnecker R. Epstein–Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene. 2004;23:8619–8628.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.